secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210286
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026
--------------------------------------------------------------------

- Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.
- Cash $279.8M at March 31, 2026, down from $317.0M; runway expected into 2028.
- R&D expense rose to $27.6M, driven by avexitide trial costs and $4M Gubra milestone.
- Phase 3 LUCIDITY for avexitide (PBH) enrollment complete; topline data in Q3 2026.
- Early biomarker data from LUMINA Phase 1 for AMX0114 (ALS) expected at ENCALS June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/0001193125-26-210286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/amlx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer